Abstract: Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.

Abstract: The present invention relates to composition at least including (A) at least one epoxy-group terminated polyoxazolidinone, derived from at least one polyisocyanate compound and at least one aliphatic polyepoxide compound, (B) at least one compound having at least one group that is reactive towards terminal epoxy-groups, and (C) at least one solvent. The molar ratio of the epoxy groups of the polyepoxide compound to the isocyanate groups of the polyisocyanate compound is 50:1 to 2.4:1. The at least one epoxy-group terminated polyoxazolidinone is present in an amount of 50 to 95% by weight, in respect of the solid content of the composition. The sum of all components in respect of the solid content of the composition adds up to 100% by weight and where the solid content of the composition is at least 35% by weight.

Abstract: The invention relates to compositions containing A) at least one component having at least one uretdione group, B) at least one component having at least one hydroxyl group, C1) of at least one catalyst, containing a structural element of the general formula (I) and/or (II), wherein R1, R2, R3, R4, R5 and R6 independently of each other represent the same or different radicals meaning saturated or unsaturated, linear or branched, aliphatic, cycloaliphatic, araliphatic or aromatic organic radicals with 1 to 18 carbon atoms that are substituted or unsubstituted and/or have heteroatoms in the chain, the radicals being capable of forming, even when combined with each other and optionally together with an additional heteroatom, rings with 3 to 8 carbon atoms that can optionally be further substituted, wherein R3, R4, R5 and R6 independently of each other can also represent hydrogen, and R7 represents hydrogen or a carboxylate anion (COO?), and C2) at least one catalyst containing at least one N,N,N?-trisubstituted